Skip to main content

Shares in Nanogen Surge 21 Percent on News of FDA Clearance

NEW YORK, March 29 (GenomeWeb News) - Shares in Nanogen were up 21.11 percent, or $.57, at $3.27 in mid-afternoon trading after the company this morning said it won 510(k) clearance from the US Food and Drug Administration to sell one of its tests.


The product, called StatusFirst CHFNT-proBNP EDTA plasma test, is used to diagnose individuals suspected of having congestive heart failure. It is the first 510(k) clearance for Nanogen.


Nanogen said it will continue developing its StatusFirst CHF whole blood test with an eye for FDA clearance.


The cleared test is the result of a collaboration between Nanogen and Princeton BioMeditech Corporation. The companies co-developed and will co-market the product, Nanogen said.


PBM will manufacture the product under contract with Nanogen. The test is sold in conjunction with the DXpress reader, a qualitative and quantitative instrument supplied by PBM.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.